Isomorphic Labs raises $5 billion as its AI-designed medicines move toward clinical trials
Isomorphic Labs has announced a $5 billion Series C funding round, giving the AI drug discovery company substantial backing as it prepares therapeutic candidates for clinical trials. Greenoaks and Sequoia Capital co-led the financing, with participation from Andreessen Horowitz, Alphabet and existing investors. The company was founded in 2021 and is led by Demis Hassabis, with Max Jaderberg serving as president, according to PRNewswire
The company’s drug design engine, called IsoDDE, combines simulation models intended to help researchers explore and refine molecules across different therapeutic areas. Isomorphic says its internal programs include oncology and immunology, alongside work with pharmaceutical partners. It describes positive preclinical results and says the funding will support its models, candidate pipeline and the infrastructure needed to advance into clinical development.
The size of the round reflects the scale of the problem investors are backing. A promising molecule has to satisfy several demands at once. It needs to interact with its intended target, reach the relevant part of the body, and have a workable safety profile. Improving one property can worsen another. AI tools offer a way to explore those choices more quickly and help researchers decide which candidates deserve experimental work.
Clinical trials introduce a further test. Predictions and laboratory results can guide a program, while studies in people establish whether a treatment can deliver its intended benefit with acceptable risks. Isomorphic’s funding announcement describes progress toward that stage. It provides no clinical efficacy results for its candidates.
That distinction makes the next milestones especially interesting. The company’s eventual trial entries will give the wider industry concrete programs to follow, including what diseases they target, how the medicines work, and how they perform over time. TechCrunch reports that taking candidates into clinical trials is a central aim of the new financing.
For the startup ecosystem, the round also shows how much capital AI companies can attract when they address an expensive scientific bottleneck. Isomorphic now has the resources to pursue several parts of drug development in parallel. Its scientific results will determine how much of that investment translates into medicines that reach patients.